Trial Profile

A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Mar 2025 According to an Acumen Pharmaceuticals media release, Company expects topline results in late 2026.
12 Mar 2025 According to an Acumen Pharmaceuticals media release, data from this will be presented at the International Conference on Alzheimer's and Parkinsons Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting. on April 1, 2025, 2:30-2:45 p.m. CES, in Austria Center Vienna, Hall A San Diego, Calif. and April 7, 2025, 2:24 p.m. PT in San Diego Convention Center, 25C.
19 Dec 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com